VALEN LABS — Peptide Stacking Knowledge Base

Definitive Stack-Recommendation Reference (Website Publication Master)

Document type: Internal research knowledge base → source for public-facing protocol cards Version: 1.0 Compiled: 2026-08-09 Intended market: EU + Serbia Status: FOR RESEARCH USE ONLY (RUO)

⚠️ MANDATORY PUBLICATION DISCLAIMER (attach to every card that ships to the website)

RESEARCH USE ONLY. All peptides described in this knowledge base are unapproved investigational substances. They are not registered as medicinal products in the EU, the Republic of Serbia, or most other jurisdictions, and they are not intended to diagnose, treat, cure, or prevent any disease. This document is educational material describing research protocols used in the scientific literature and the research community — it is not medical advice and must not be used as a self-administration guide. Several of these substances (e.g., BPC-157, TB-500, CJC-1295, GHRP-2, GHRP-6) have been flagged by the U.S. FDA as bulk substances that may present significant safety risks when compounded, and TB-500 / BPC-157 appear on the WADA Prohibited List (S0, non-approved substances) for athletes. Nothing here is intended for human or veterinary consumption. Always comply with local law (EU Cosmetics/Medicines frameworks, Serbian Law on Medicines and Medical Devices). Keep this banner intact on all published cards.

TABLE OF CONTENTS

1. Stack Principles — Why We Stack
2. The Three Functional Axes
3. GHRH/GHRP Logic (the GH Axis, Properly Understood)
4. Evidence Labels Used in This Document
5. The Golden Rules of Stacking (read before anything else)
6. Protocol Cards (12)
   • Card 01 — GLOW: GHK-Cu + BPC-157 + TB-500 (skin / tissue regeneration)
   • Card 02 — Wolverine: BPC-157 + TB-500 (injury recovery)
   • Card 03 — CJC-1295 no DAC + Ipamorelin (GH / body recomp)
   • Card 04 — Tesamorelin + Ipamorelin (visceral fat / recomposition)
   • Card 05 — NAD+ + MOTS-c (mitochondrial energy)
   • Card 06 — GLP-1 (Semaglutide/Tirzepatide) + BPC-157 (GI side-effect mitigation)
   • Card 07 — Retatrutide + Tesamorelin (+ MOTS-c) (muscle-sparing fat loss)
   • Card 08 — KPV + BPC-157 (gut / systemic inflammation)
   • Card 09 — Sermorelin + Ipamorelin (beginner GH / anti-aging)
   • Card 10 — CJC-1295 no DAC + Ipamorelin + MK-677 (advanced GH, high-monitoring)
   • Card 11 — AOD-9604 + HGH Frag 176-191 (+ Tesamorelin) (targeted lipolysis)
   • Card 12 — Thymosin Alpha-1 + Epitalon + GHK-Cu (immune / longevity)
7. Avoid-List — Bad Combinations and Why
8. Beginner vs Advanced Stack Tiers
9. Reconstitution, Storage, and Syringe-Mixing Rules
10. Lab Monitoring Panel (non-negotiable for GH-axis stacks)
11. Full Bibliography with URLs

1. STACK PRINCIPLES — WHY WE STACK

1.1 The core idea

A peptide stack is the deliberate combination of two or more peptides whose mechanisms are complementary but not redundant, chosen so that the combined effect is greater than the sum of the parts (or, more honestly and more commonly, so that the user gets broader coverage at lower per-compound doses).

The scientific justification for stacking is not "more is more." It is:

1. Mechanistic complementarity — different peptides hit different receptors/signalling cascades that converge on the same goal (e.g., GH release via both GHRH-receptor and ghrelin-receptor activation, documented as synergistic by Veldhuis & Bowers).
2. Dose-sparing — combining allows each compound to run at a lower dose, which in principle lowers dose-dependent side effects per compound.
3. Tissue coverage — repair stacks pair local (near-injury) and systemic (whole-body) mechanisms so the injury site and the systemic repair environment are both supported.
4. Temporal layering — compounds with different onset times (BPC-157 anti-inflammatory within days, TB-500 cell-migration over 1–2 weeks, GHK-Cu collagen remodelling over 4–8 weeks) create a staggered, continuous repair signal.

The honest caveat that must appear on every published card: most stacks have zero formal clinical validation as combinations. The synergy claims rest on (a) preclinical mechanism data for each component, (b) endocrinology principles (GHRH+GHRP synergy is the best-documented one), and (c) community practice that has become de-facto convention (GLOW, Wolverine). We state which is which on every card.

1.2 Why single-peptide protocols underperform

• GHRH-only (e.g., CJC-1295 no DAC alone, sermorelin alone): produces a modest GH pulse that is partially blunted by somatostatin tone; the pituitary does not reach maximal output.
• GHRP-only (ipamorelin alone): gives a sharp GH spike but it is short-lived and loses effectiveness over time; the ghrelin-receptor pathway alone does not sustain IGF-1 elevation meaningfully — this is why ipamorelin is frequently described by prescribers as "a waste as monotherapy" and why it is almost always paired with a GHRH analog.
• Repair peptides alone (BPC-157 only): excellent at the injury site, but a systemic environment of unresolved inflammation and poor blood flow limits the ceiling of what local repair can achieve; TB-500 adds the systemic cell-mobilization layer.
• GHK-Cu alone: excellent for skin/collagen signalling, but without an angiogenesis/anti- inflammation layer (BPC-157, TB-500) tissue repair is slower in practice.

1.3 What a stack is NOT

• It is not five GH-stimulators at once (that is how you get insulin resistance, moon face, edema, and carpal-tunnel symptoms — see Avoid-List).
• It is not mixing everything into one vial (stability issues, especially with copper chelates).
• It is not a substitute for training, protein intake, sleep, or calorie control. Every published card must carry this line: "Peptides are amplifiers of a healthy protocol, not replacements for one."

2. THE THREE FUNCTIONAL AXES

Every peptide in the VALEN LABS catalogue can be mapped to one (or occasionally two) of three axes. Rule: within a single protocol, never stack two peptides from the same axis in an attempt to "double up" — instead, stack across axes.

AXIS A — GH / IGF-1 axis (growth hormone secretagogues)

| Peptide | Role | Half-life (community-cited) | |---|---|---| | CJC-1295 no DAC (Mod GRF 1-29) | GHRH analog — tells pituitary to make GH | ~30 min | | CJC-1295 with DAC | GHRH analog, albumin-bound — sustained signal | ~6–8 days | | Sermorelin (GRF 1-29) | GHRH analog, the original clinically-studied one | ~10–15 min | | Tesamorelin | GHRH analog, FDA-approved for HIV lipodystrophy | ~1–2 h (dosed daily) | | Ipamorelin | GHRP (ghrelin-receptor agonist) — triggers release of GH; selective (no cortisol/prolactin) | ~2 h | | GHRP-2 / GHRP-6 | Older GHRPs — strong GH release but raise cortisol/prolactin | ~30 min | | Hexarelin | GHRP — potent, also cortisol-active | ~20 min | | MK-677 (Ibutamoren) | Oral ghrelin mimetic — tonic GH elevation | ~24 h | | HGH Frag 176-191 / AOD-9604 | GH fragments — lipolysis-selective, no GH release | ~1 h |

Cardinal rule of Axis A: pair exactly one GHRH (make) with one GHRP (release). That is the entire synergy. Two GHRPs, or two GHRHs, or a GHRH-with-DAC plus a daily GHRP, all violate the pulsatility logic and increase side effects without increasing benefit.

AXIS B — Tissue repair / regeneration

| Peptide | Role | |---|---| | BPC-157 | Angiogenesis (VEGFR2), fibroblast activation, tendon/ligament/muscle/gut repair, anti-inflammatory | | TB-500 (Thymosin Beta-4 fragment) | Actin binding (LKKTETQ), cell migration, systemic repair mobilization | | GHK-Cu | Collagen/elastin synthesis, ECM remodelling, gene-expression modulation (anti-aging "master" copper peptide) | | KPV | Anti-inflammatory tripeptide (α-MSH fragment), NF-κB suppression, gut-mucosa calming | | Thymosin Alpha-1 | Immune modulation, T-cell function (immune axis — repair-adjacent) |

Cardinal rule of Axis B: repair stacks are layered, not doubled — local (BPC-157), systemic (TB-500), structural (GHK-Cu), inflammatory-control (KPV). Each layer is a different mechanism, so stacking them is legitimate. What is NOT legitimate is running two angiogenesis-drivers at high dose in a cancer-history patient (see Avoid-List).

AXIS C — Metabolic / energy / body-composition

| Peptide | Role | |---|---| | Semaglutide | GLP-1 receptor agonist — appetite, gastric emptying, glucose | | Tirzepatide | GLP-1 + GIP dual agonist — weight loss, glucose | | Retatrutide | GLP-1 + GIP + glucagon triple agonist — investigational, largest weight loss to date | | Tesamorelin | GH-mediated visceral-fat targeting (also Axis A — a cross-axis compound) | | AOD-9604 | Lipolysis-selective GH fragment (β3-adrenergic signalling) | | MOTS-c | Mitochondrial-derived peptide — insulin sensitivity, fat oxidation | | NAD+ / NR / NMN | Redox cofactor — cellular energy, sirtuin support | | SS-31 (elamipretide) | Mitochondrial cardiolipin stabilization (investigational) |

Cardinal rule of Axis C: a metabolic stack should combine appetite control (GLP-1 class) + muscle preservation (GH axis via tesamorelin/sermorelin or AOD-9604 lipolysis) + cellular energy (NAD+/MOTS-c) — one mechanism per slot.

3. GHRH/GHRP LOGIC — THE GH AXIS, PROPERLY UNDERSTOOD

This is the single most important concept in GH-peptide stacking, and it must be explained clearly on the website because 80% of community errors come from misunderstanding it.

3.1 The physiology in one paragraph

Growth hormone release from the anterior pituitary is controlled by a two-part rheostat: GHRH (stimulatory) and somatostatin (inhibitory), plus a third input, ghrelin (stimulatory, via the GHSR-1a receptor). Natural GH secretion is pulsatile — bursts, not a constant drip — with the largest pulses at night (slow-wave sleep) and in response to fasting, stress, and exercise.

• A GHRH analog (CJC-1295 no DAC, sermorelin, tesamorelin) raises the "stimulatory" signal — it pushes the pituitary toward synthesizing and readying GH.
• A GHRP / ghrelin mimetic (ipamorelin, GHRP-2/6, hexarelin, MK-677) both releases a GH pulse and antagonizes somatostatin — it pulls the trigger and simultaneously removes the brake.

The synergy: activating GHRH-receptor and ghrelin-receptor simultaneously produces a GH pulse larger than the arithmetic sum of either alone — a documented endocrine principle (Veldhuis & Bowers, 2009; the classic framework used by every modern peptide clinic). One without the other gives a sub-maximal pulse.

3.2 Why "no DAC" and why fasting

• DAC (Drug Affinity Complex) is an albumin-binding modification that stretches CJC-1295's half-life from ~30 minutes to ~6–8 days. DAC versions create a tonic, sustained GH signal. Community and clinical consensus is that this (a) desensitizes the somatotroph, (b) causes more water retention, and (c) defeats the pulsatility logic that makes GH signalling physiological. The no-DAC (Mod GRF 1-29) version is preferred for daily GHRH+GHRP protocols. Note: there are zero published human studies on CJC-1295 no DAC specifically — its dosing is extrapolated from the GRF 1-29 pharmacology. State this on the card.
• Fasting before injection matters more than most people realize because of somatostatin. Eating → insulin rise → somatostatin tone rises → the GH pulse is blunted. Community-standard protocol: inject after a 2-hour fast (no calories), wait 30–60 minutes before eating afterward. Pre-bed (2–3 h after dinner) and fasted morning are the two canonical windows.

3.3 Why Ipamorelin is the default GHRP

• Selectivity: ipamorelin is the first selective GH secretagogue — it releases GH dose-dependently without elevating ACTH, cortisol, or prolactin, even at doses >200× the GH ED50 (Raun et al., Eur J Endocrinol 1998). GHRP-2 and GHRP-6, by contrast, do raise ACTH/cortisol — a stress- hormone side effect that stacks badly with everything else (see Avoid-List).
• Short half-life (~2 h) → clean pulsatile profile → fits daily 1–3× dosing.

3.4 Cycle logic for the GH axis

• Somatotroph receptors downregulate under continuous stimulation → response fades → cycle on/off is mandatory: community-standard 8–12 weeks on, 4 weeks off for injectable GHRH+GHRP; MK-677 similar (or 5-on/2-off patterns).
• Monitor IGF-1 (aim for upper-normal, not supraphysiological), fasting glucose / HbA1c / HOMA-IR (GH is a counter-regulatory hormone — it makes you insulin-resistant at high levels), and water retention / blood pressure.

4. EVIDENCE LABELS USED IN THIS DOCUMENT

Every card is tagged. Use the same tags on the website.

| Label | Meaning | |---|---| | 🟢 CLINICAL | Mechanism and/or outcome supported by published human trials (peer-reviewed). | | 🟡 MIXED | Strong preclinical/mechanistic data + limited human data; protocol is community-standard. | | 🔴 COMMUNITY | No clinical evidence. Protocol is community convention (Reddit/forums/clinics), extrapolated from single-compound data. Publish with extra hedging. |

Additional flags used:

• WADA ⛔ — prohibited in-competition/at-all-times for athletes (BPC-157, TB-500, GHRPs, GHRH analogs, AOD-9604, HGH fragments).
• FDA-FLAGGED — listed by the U.S. FDA (2023 compounding lists) as a bulk substance that may present significant safety risks.
• RUO ONLY — research use only, no approved human indication anywhere in EU/Serbia.

5. THE GOLDEN RULES OF STACKING (publish as a standalone infographic)

1. One axis, one compound. Never double up within an axis. One GHRH + one GHRP is the entire GH stack. Adding a third GH-stimulator adds side effects, not results.
2. One new peptide at a time. Start a new compound, hold everything else steady for 2 weeks, assess tolerance, then add the next. If something goes wrong you must know which compound caused it.
3. No new peptides during the first 4 weeks of a GLP-1. Establish tolerance to semaglutide/ tirzepatide/retatrutide first; add BPC-157 etc. only after the titration phase.
4. Fasting rules are non-negotiable for Axis A. 2 h fast before, 30–60 min after, for every GHRH/GHRP injection.
5. Cycle everything. 4–12 weeks on, 2–4 weeks off (exact per card). GH-axis stacks must be cycled to avoid receptor desensitization and insulin resistance.
6. Never mix in the vial. Draw into one syringe only immediately before injecting, and only for documented-compatible pairs (BPC-157 + TB-500; CJC-1295 no DAC + ipamorelin). GHK-Cu stays in its own syringe/vial. GLP-1s are never mixed with anything.
7. Labs before, during, and after any GH-axis or metabolic stack (IGF-1, glucose, HbA1c, HOMA-IR, lipids, liver/kidney, CRP). See Section 10.
8. Cancer history = stop. Anything angiogenic (BPC-157, TB-500, GHK-Cu at high dose) or GH/IGF-1-raising (all of Axis A, MK-677) is contraindicated with active cancer. Telomerase- activators (Epitalon) likewise.
9. Quality gate. Only use third-party-tested product (HPLC ≥99%, mass-spec identity, verifiable COA — the Janoshik-style testing ecosystem is the community standard for COA verification). Lyophilized storage −20 °C; reconstituted 2–8 °C and used within 4–6 weeks.
10. Peptides are amplifiers, not replacements. Protein 1.6–2.2 g/kg, resistance training, 7–8 h sleep, and a real caloric surplus/deficit are the actual protocol. The peptides are the multiplier.

6. PROTOCOL CARDS

CARD 01 — GLOW STACK (GHK-Cu + BPC-157 + TB-500)

Tags: 🟡 MIXED (per-component clinical basis; combination is community convention) | WADA ⛔ | RUO ONLY

Goal

Whole-body "glow": skin quality, collagen density, hair, wound/tissue regeneration, and systemic inflammation control. The aesthetic-regeneration flagship of the niche.

Rationale (why these three)

• GHK-Cu — stimulates collagen/elastin synthesis, ECM remodelling, antioxidant gene expression (Pickart review, IJMS 2018). The structural layer.
• BPC-157 — angiogenesis (VEGFR2), fibroblast activation, anti-inflammatory; drives local repair and improves blood supply. The local repair layer.
• TB-500 — thymosin β-4 fragment; actin binding (LKKTETQ), cell migration, systemic mobilization of repair resources. The systemic layer.
• Together: structure + local repair + systemic mobilization. Each is a different mechanism, so the stack is legitimate Axis B layering. The fixed 5:1:1 blend ratio reflects GHK-Cu's lower potency (needs ~5× more mass) — the typical 70 mg blend vial = GHK-Cu 50 mg + TB-500 10 mg + BPC-157 10 mg.

Peptides & doses (community-standard protocol)

| Component | Dose per injection | Notes | |---|---|---| | Total blend | 2,000–2,500 mcg (2–2.5 mg) | Once daily, subQ | | — of which GHK-Cu | ~1,400–1,700 mcg | From 5:1:1 blend | | — of which BPC-157 | ~280–330 mcg | | | — of which TB-500 | ~280–330 mcg | |

DIY (separate vials, flexible titration): | Component | Dose | Frequency | |---|---|---| | GHK-Cu | 1–2 mg | Daily | | BPC-157 | 250–500 mcg | Daily | | TB-500 | 2–2.5 mg | 2×/week |

Timing

• Once daily, subQ (abdomen or thigh), rotate sites. No fasting requirement (not a GH-axis stack), though many users inject pre-bed or fasted AM for convenience.
• For a localized injury, inject BPC-157-containing mix near the site; GHK-Cu and TB-500 are systemic.

Cycle

• 4 weeks on, 2–4 weeks off (community standard). Extended protocols run 4–8 weeks on.
• Rationale for cycling: receptor downregulation on continuous stimulation, plus the shared reconstitution clock (~4 weeks stability ceiling for the copper chelate in the fridge).

What to expect (timeline, from community + component data)

| Window | Effect | |---|---| | Days | Reduced inflammation, faster wound/incident recovery | | 1–2 weeks | Systemic repair mobilization (TB-500 layer) | | 4–8 weeks | Skin texture/firmness, collagen remodelling (GHK-Cu layer) | | 8–12+ weeks | Visible wrinkle/skin-quality improvement; hair changes 3–6 months |

Notes

• "Copper uglies": anecdotal transient worsening of skin appearance (puffiness/breakouts) in the first 1–3 weeks — thought to relate to MMP upregulation before collagen remodelling catches up. Not well-studied; inform users.
• Blend stability: the copper chelate sets the stability ceiling. Reconstituted GLOW is good ~4 weeks at 2–8 °C, upright, light-protected. Color shift from pale azure-blue toward green-brown or haze = discard. Freeze only the lyophilized powder, never the reconstituted blend.
• Syringe: mixing the three in one syringe at injection time is standard practice; keep GHK-Cu out of long-term co-storage with other peptides.
• KLOW variant: GLOW + KPV (anti-inflammatory 4th layer) exists in the community (80 mg vials) — see Card 08 for KPV logic.
• Cancer history: avoid (angiogenesis + collagen signalling; theoretical tumor-feeding risk).

Sources

[1] [2] [3] [4] [5] [35] [83] [84] [85] — see Bibliography.

CARD 02 — WOLVERINE STACK (BPC-157 + TB-500)

Tags: 🟡 MIXED (BPC-157: preclinical + 3 small human studies; TB-500: preclinical + tiny human combination data) | WADA ⛔ | RUO ONLY

Goal

Injury recovery: tendonitis, ligament sprains/tears, muscle tears, joint pain, post-surgical repair, chronic overuse injuries. The "get back to training" stack.

Rationale

• BPC-157 — accelerates tendon/ligament/muscle healing: upregulates growth-hormone receptors on fibroblasts, drives angiogenesis and collagen synthesis, modulates TNF-α/IL-6 inflammation. Best delivered near the injury (local concentration).
• TB-500 — systemic: mobilizes repair cells, organizes actin for migration, anti-inflammatory (regulates thymosin β-4 pathways). Delivered anywhere (systemic).
• Community shorthand: "BPC-157 builds the road; TB-500 brings the traffic."
• The only human data on the combination is a small retrospective (Lee & Padgett 2021, 16 patients, knee injections of BPC-157 ± TB-4: combination group reported improvement; 3 of 4 improved) — thin, but the only human signal that exists for the pair.

Peptides & doses

Phase 1 — Loading (weeks 1–4): | Component | Dose | Frequency | Route | |---|---|---|---| | BPC-157 | 250–500 mcg | Daily | SubQ near injury site | | TB-500 | 2.5 mg | 2×/week | SubQ (systemic) |

Phase 2 — Maintenance (weeks 5–8): | Component | Dose | Frequency | |---|---|---| | BPC-157 | 250–500 mcg | Daily | | TB-500 | 2.5 mg | 1×/week |

Timing

• BPC-157 daily at a consistent time (AM or PM); TB-500 on its own 2×/week schedule. No fasting requirement. Can be drawn into the same syringe (documented-compatible pair) or injected separately.

Cycle

• 4–12 weeks total depending on injury severity (4 weeks loading + 4 weeks maintenance is the community baseline; chronic cases up to 12 weeks). Then 4 weeks off before re-evaluation.
• Severe/chronic cases sometimes run longer continuous protocols under medical supervision — flag as off-standard.

What to expect

• Reduced pain/inflammation within days (BPC-157 layer); functional recovery and mobility improving over 2–6 weeks; structural consolidation continues for weeks after the cycle ends.
• Community consensus: recovery feels "more complete" than single-peptide protocols because local + systemic layers run simultaneously.

Notes

• Evidence honesty: BPC-157's human evidence base is exactly three small published studies (all led by E. Lee; a 2025 pilot IV-infusion safety study in 11 participants, and the 2021 retrospective knee review). No blinded, placebo-controlled, adequately powered human trial exists. Preclinical literature is extensive and positive (gastric/ulcer, tendon, muscle, bone, nerve models — Sikiric group, decades of work). Publish with this framing — it is a differentiator for VALEN LABS to be honest.
• FDA: BPC-157 and TB-500 were added (Sept 2023) to the FDA 503A bulk-drug list of substances that may present significant safety risks; they are WADA S0 prohibited for athletes.
• TB-500 is injectable-only (not orally active). BPC-157 has oral forms in the community but injectable is the standard for injury protocols; oral BPC-157 is controversial (see Avoid-List).
• Cancer history: avoid (angiogenic mechanism; VEGFR2 upregulation — a 2023 pharmaceutical review flagged the theoretical tumor-angiogenesis concern).

Sources

[12] [13] [14] [15] [16] [52] [53] [54] [55] [56] [86] [87]

CARD 03 — CJC-1295 no DAC + IPAMORELIN

Tags: 🟡 MIXED (GHRH+GHRP synergy: documented endocrine science; specific no-DAC dosing: zero human trials, community-extrapolated) | WADA ⛔ | RUO ONLY | FDA-FLAGGED (CJC-1295)

Goal

Lean-mass gain, fat loss, sleep quality, recovery, anti-aging — the "recomp" GH stack. The most popular injectable GH secretagogue combination in the niche.

Rationale

• CJC-1295 no DAC (Mod GRF 1-29) — GHRH analog: tells the pituitary to synthesize/release GH; ~30-min half-life → sharp, physiological pulse.
• Ipamorelin — selective GHRP: releases GH, antagonizes somatostatin, no cortisol/prolactin effect (Raun 1998).
• Simultaneous GHRH-receptor + ghrelin-receptor activation produces a supra-additive GH pulse (Veldhuis & Bowers synergy framework). This is the best-documented synergy in all of peptide stacking.
• Ipamorelin as monotherapy "fails" in practice (weak IGF-1 response over time) — the GHRH partner is what sustains results.

Peptides & doses

| Component | Minimum (1×/day) | Standard (2×/day) | Max (3×/day) | |---|---|---|---| | CJC-1295 no DAC | 100 mcg | 100–200 mcg | 100–200 mcg | | Ipamorelin | 100–200 mcg | 200 mcg | 200–300 mcg |

• Typical starting protocol: 100 mcg each, pre-bed, titrate up every 1–2 weeks to 200 mcg each.
• Can be drawn into the same syringe (standard community practice; documented-compatible).

Timing

• Fasted only. 2 h no food before, 30–60 min no food after. Insulin blunts the GH response.
• Canonical windows: pre-bed (primary — amplifies nocturnal GH surge), fasted AM, and optionally post-workout (fasted window).
• 1×/day = pre-bed; 2×/day = fasted AM + pre-bed; 3×/day = AM + pre-workout + pre-bed (advanced).

Cycle

• 8–12 weeks on, 4 weeks off (community standard). Some clinics run 3 months on / 1 month off.
• Monitor IGF-1 (target upper-normal range), fasting glucose, water retention.

What to expect

| Window | Effect | |---|---| | 1–2 weeks | Deeper sleep, vivid dreams, better recovery | | 2–4 weeks | Energy, mood, skin/tissue quality | | 6–12 weeks | Body-composition changes (slow, incremental — GH peptides are NOT anabolic drugs; frame expectations honestly) | | After cycle | IGF-1 returns toward baseline; benefits partially retained if training/nutrition held |

Notes

• Zero human studies on CJC-1295 no DAC. Doses are extrapolated from GRF 1-29 pharmacology and community consensus. CJC-1295 (with DAC) was studied in a small human trial (increased heart rate and vasodilation reported); FDA flagged CJC-1295 for compounding immunogenicity/characterization concerns. State all of this.
• CJC-1295 with DAC is a different compound (weekly dosing, tonic signal, more water retention) — see Card comparison in Avoid-List; VALEN LABS recommends the no-DAC form for this protocol.
• Not for diabetics/pre-diabetics without monitoring; watch fasting glucose.
• Over-50 users respond less — consider tesamorelin-based stack (Card 04) for visceral fat or sermorelin (Card 09) for gentler anti-aging.

Sources

[6] [7] [8] [9] [10] [11] [45] [46] [66] [67]

CARD 04 — TESAMORELIN + IPAMORELIN

Tags: 🟢 CLINICAL (tesamorelin component; combination itself is 🟡 community) | WADA ⛔ | RUO ONLY

Goal

Visceral (belly) fat reduction with lean-mass protection — the "stubborn midsection" stack, popular in older/over-40 users and GLP-1 adjunct protocols.

Rationale

• Tesamorelin — GHRH analog with the deepest clinical fat-loss track record in the GH family: FDA-approved (Egrifta) for HIV-associated lipodystrophy; trials show ~15–18% visceral adipose tissue reduction over 26 weeks while preserving lean mass (Falutz et al., NEJM 2007; 12-month data 2010). Visceral fat is the metabolically dangerous depot (drives inflammation, insulin resistance) and is notoriously resistant to diet alone.
• Ipamorelin — adds the GHRP pulse on top of tesamorelin's GHRH signal (same GHRH+GHRP synergy logic as Card 03) so the GH pulse is larger, and covers recovery/sleep benefits.
• Tesamorelin alone can carry the protocol; ipamorelin is the amplifier. This is why the pair is the community-standard "fat-loss + muscle-preservation" GH stack.

Peptides & doses

| Component | Dose | Frequency | Timing | |---|---|---|---| | Tesamorelin | 1–2 mg | Daily (5 on/2 off common) | Pre-bed, fasted (≥2 h after last meal) | | Ipamorelin | 100–300 mcg | Same schedule | Same syringe or same session |

• Clinic-standard tesamorelin solo dose: 1 mg/day (the FDA-studied dose, = 25 units on a U-100 syringe from a 2.5 mL-reconstituted 5 mg vial).
• 5 days on / 2 days off patterns are common to reduce cost and receptor fatigue.

Timing

• Pre-bed, 30–90 min before lights-out, ≥2–3 h after last calories. Evening alignment with the nocturnal GH surge. Alcohol and late snacks blunt the response.
• SubQ, rotate abdomen/thigh.

Cycle

• 12–24 weeks for meaningful visceral-fat results (clinical trials measured at 26 weeks).
• Community pattern: 8 weeks on / 8 weeks off or 12 weeks on / 4 off; maintain resistance training and protein 1.6–2.0 g/kg during the cycle.

What to expect

| Window | Effect | |---|---| | 4–8 weeks | Waist measurement changes begin (slow) | | 12–16 weeks | Visible visceral-fat reduction, lean mass held | | 26 weeks | Clinical benchmark: 15–18% VAT reduction (trial data at 2 mg/day) |

Notes

• Tesamorelin raises blood sugar in trials (GH is counter-regulatory): monitor fasting glucose and HbA1c. Fluid retention and joint aches are the commonly reported side effects.
• Works best with resistance training + protein (otherwise the GH signal does not translate to lean-mass protection).
• Strong candidate to stack with GLP-1s (Card 06/07) because it attacks the fat depot that GLP-1s leave behind while protecting muscle.
• Expectation framing: 1 mg/day is the studied dose; community 2 mg is aggressive — treat as advanced.

Sources

[17] [18] [19] [20] [21] [22] [23] + Falutz 2007/2010 in Bibliography.

CARD 05 — NAD+ + MOTS-c (Mitochondrial Energy Stack)

Tags: 🟡 MIXED (NAD+ IV: clinical use in clinics; MOTS-c: strong preclinical, minimal human) | RUO ONLY

Goal

Cellular/mitochondrial energy, fatigue, metabolic flexibility, endurance, healthy aging. The "longevity engine room" stack.

Rationale

• NAD+ — central redox cofactor; declines with age; supports sirtuin activity and ATP production. IV NAD+ is the clinical standard (500–1,000 mg infusions); injectable/IM and oral precursors (NR/NMN 250–500 mg/day) are the at-home community alternatives.
• MOTS-c — mitochondrial-derived peptide; in preclinical work it shifts cells toward fat oxidation, improves insulin sensitivity, and protects against age-related metabolic decline (Lee et al., Nat Commun 2015). Community dosing: 5–10 mg 2–5×/week.
• Rationale for pairing: NAD+ supplies the redox fuel; MOTS-c programs mitochondria to burn fat — "fuel + firmware." SS-31 (elamipretide) is the third mitochondrial peptide sometimes added (cardiolipin stabilization) but is more expensive and more investigational — treat as optional advanced layer.

Peptides & doses

| Component | Dose | Frequency | Route | |---|---|---|---| | NAD+ | 500–1,000 mg (IV) OR 50–200 mg | IV: 2–4 loading infusions/2 weeks, then monthly; IM: 2–3×/week; SubQ: 50–100 mg/dose (≤50 mg/site) | IV / IM / SubQ | | MOTS-c | 5–10 mg | 2–3×/week (or 5 mg every 5 days) | SubQ | | Optional: SS-31 | 10–20 mg (community range; no human consensus dose) | 2–3×/week | SubQ |

Timing

• NAD+ is typically given daytime (some users report stimulation); MOTS-c morning (community convention — no formal data). No fasting requirement.

Cycle

• NAD+: loading phase then maintenance; MOTS-c: 4–6 week cycles, 2–4 weeks off (community).
• MOTS-c does not require GH-axis-style cycling (no receptor downregulation documented), but community practice cycles for cost/effect.

What to expect

• Energy/focus improvements within 2–4 weeks (NAD+ layer is the faster one); metabolic/endurance and insulin-sensitivity effects building over 6–12 weeks (MOTS-c layer).

Notes

• Evidence honesty: MOTS-c human data is minimal (a few small trials in the 2020s; the famous insulin-sensitivity work is rodent). NAD+ IV has wide clinic use but the "anti-aging" claims remain debated — frame as cellular-energy support, not life-extension.
• NAD+ infusions: flushing, nausea possible; IM/subQ site irritation is common.
• MOTS-c is a mitochondrial peptide — do not co-mix with GHK-Cu in one syringe (community rule; see Section 9). Separate injections.
• Pairs well with GHK-Cu for the "longevity foundation" (energy + structural repair).

Sources

[24-ish NAD+/MOTS-c refs — see Bibliography: MOTS-c dosing guides, PeptIQ, Healthspan]

CARD 06 — GLP-1 (SEMAGLUTIDE / TIRZEPATIDE) + BPC-157

Tags: 🟢 CLINICAL (GLP-1 component, GI side effects well documented) + 🔴 COMMUNITY (BPC-157 mitigation layer — preliminary, anecdotal) | RUO ONLY

Goal

Weight loss with GI side-effect mitigation and gut protection during GLP-1 titration. The most commonly prescribed "support stack" in 2025–2026 clinics.

Rationale

• GLP-1 receptor agonists (semaglutide, tirzepatide) slow gastric emptying and suppress appetite — that is the mechanism, and it is also the source of the side effects: nausea, bloating, reflux, constipation, vomiting during dose escalation (documented in every label and trial; the GI burden is the #1 reason for discontinuation).
• BPC-157 — gastric-mucosa protection, gut-barrier support, anti-inflammatory, and tissue repair; in the community and in a growing number of clinics it is used specifically to let patients tolerate GLP-1 titration and reduce nausea/gut discomfort. Clinical evidence for this specific use is preliminary; the anecdotal signal is strong.
• Secondary logic: GLP-1 users in caloric deficit get connective-tissue strain and lose lean mass — BPC-157 adds a repair/anti-inflammatory layer.

Peptides & doses

| Component | Dose | Frequency | Notes | |---|---|---|---| | Semaglutide or Tirzepatide | Per label titration (e.g., sema 0.25→1 mg/wk; tirz 2.5→15 mg/wk) | Weekly | Establish tolerance FIRST (2–4 weeks) | | BPC-157 | 250–500 mcg | Daily | SubQ; start only after GLP-1 baseline established |

Timing

• BPC-157 daily, morning or pre-bed, no fasting requirement. Separate injection sites from the GLP-1 injection. Never mix GLP-1 and BPC-157 in the same syringe.
• If oral semaglutide is used: standard GI-adjunct guidance says separate any nausea meds by 30 min from the oral dose — apply the same spacing discipline to peptide support.

Cycle

• BPC-157: run through the GLP-1 titration phase (4–8 weeks), then evaluate; can be re-run in blocks. GLP-1: per label, long-term.

What to expect

• Community/clinic reports: better tolerance during dose escalation, less nausea/bloating, better protein intake (which protects muscle). Not a cure for GLP-1 GI effects — "may still occur" (honest line from vendor guides).
• If GI side effects persist >1 month at maintenance dose, standard clinical advice is to reduce the GLP-1 dose — the peptide support layer does not replace dose management.

Notes

• Sequencing rule: start the GLP-1 first, establish baseline response over 2–4 weeks, then add BPC-157. Never introduce two new compounds into a nauseated patient.
• Watch total caloric/protein intake — appetite suppression can make 1.6–2.2 g/kg protein genuinely difficult; this is the real muscle-loss driver, not the peptides.
• Tirzepatide + BPC-157 pre-mixed "blends" exist in the market — VALEN LABS does not endorse co-formulated GLP-1 blends (formulation incompatibility risk; see Section 9).

Sources

[24] [25] [26] [27] [28] [29]

CARD 07 — RETATRUTIDE + TESAMORELIN (+ MOTS-c) — Muscle-Sparing Fat Loss

Tags: 🟢 CLINICAL (retatrutide phase-2 weight loss; tesamorelin VAT trials) + 🔴 COMMUNITY (combination protocol) | RUO ONLY

Goal

Aggressive fat loss with lean-mass preservation — the advanced metabolic recomp stack.

Rationale

• Retatrutide — triple agonist (GLP-1 + GIP + glucagon): the strongest weight-loss data in the class (phase 2, NEJM 2023: up to ~24% body weight at 48 weeks at 12 mg). Mechanism: appetite + energy expenditure + fat oxidation. Glucagon agonism drives the heart-rate increase and thermogenesis side effects.
• The known problem: GLP-1-class weight loss includes 20–40% lean mass in some analyses — muscle loss is the emerging clinical complaint (see PMC review on muscle preservation in GLP-1 therapy). Tesamorelin attacks visceral fat directly while its GH signal supports lean-mass retention — the two mechanisms are complementary (retatrutide = systemic weight loss; tesamorelin = the stubborn visceral depot + muscle protection).
• MOTS-c (optional 3rd layer): mitochondrial fat oxidation + insulin sensitivity — supports the metabolic floor during a deep deficit.

Peptides & doses

| Component | Dose | Frequency | Notes | |---|---|---|---| | Retatrutide | 2–4 mg escalating to 8 mg (max 12 mg) | Weekly | Low-dose GIP-forward approach favored in recomp protocols | | Tesamorelin | 1 mg | Daily, pre-bed fasted | 5 on/2 off optional | | MOTS-c (optional) | 5 mg | 2×/week | SubQ, separate syringe |

Timing

• Retatrutide: fixed weekly injection day. Tesamorelin: pre-bed fasted. MOTS-c: morning. No co-mixing of any of these in one syringe.

Cycle

• Retatrutide: per trial protocol (48-week trials); tesamorelin: 12–26 week blocks; MOTS-c: 4–6 week blocks. Community recommendation: establish retatrutide tolerance first (12–16 weeks to stable maintenance), then add tesamorelin, then MOTS-c — one compound at a time.

What to expect

• Retatrutide alone: dramatic scale loss (trial data). With tesamorelin: deeper visceral-fat reduction (community estimate 25–35% combined vs 15–20% tesamorelin alone — treat as estimate, not data) and visibly better lean-mass retention.
• Side effects to monitor: resting heart rate (glucagon), GI burden, skin dysesthesia (sensitivity/pins-and-needles, reported with higher doses), fatigue.

Notes

• Advanced tier. Not a beginner stack. Requires labs (glucose, lipids, liver, electrolytes, cardiac review for anyone with heart history) and protein ≥1.6–2.2 g/kg + resistance training.
• Retatrutide is investigational (phase 3 completed; approval pending in EU at time of writing — check regulatory status before publishing claims).
• Avoid adding GHRP-6/MK-677 appetite-spike agents — retatrutide's appetite suppression is the point; don't fight it with ghrelin agonists.
• Steroid+retatrutide stacks (community "bodybuilding" practice) are out of scope for VALEN LABS — we do not publish on AAS.

Sources

[19] [30] [31] [32] [33] + Jastreboff NEJM 2023 in Bibliography.

CARD 08 — KPV + BPC-157 (Gut / Systemic Inflammation)

Tags: 🟡 MIXED (BPC-157 preclinical gut data; KPV anti-inflammatory preclinical) | RUO ONLY

Goal

Gut-healing and systemic inflammation control: leaky gut, IBS-type symptoms, inflammatory conditions, and as an anti-inflammatory layer in injury protocols.

Rationale

• KPV (Lys-Pro-Val) — anti-inflammatory tripeptide derived from α-MSH; suppresses NF-κB signalling, calms intestinal inflammation, supports mucosal integrity. The "brake."
• BPC-157 — drives tissue repair and angiogenesis; gastric-mucosa protection (it originated as an anti-ulcer peptide, stable in human gastric juice, with early human trials in ulcerative colitis reported by the Sikiric group in the 1990s — never fully published). The "builder."
• The pair is the most widely recommended gut-healing stack in the community: KPV quiets the inflammation so BPC-157's repair signal can work.

Peptides & doses

| Component | Dose | Frequency | |---|---|---| | KPV | 200–500 mcg | Daily | | BPC-157 | 250–500 mcg | Daily |

Timing

• Daily, subQ (abdomen preferred). No fasting requirement. Compatible to draw together at injection time (both BAC-water peptides) — or inject separately for purity of titration.

Cycle

• 4–8 weeks on, 2–4 weeks off (community standard).

What to expect

• Reduced systemic/gut inflammation within 1–3 weeks; gut-symptom improvement over 2–6 weeks.
• As an injury-stack layer: adding KPV to Wolverine (→ "KLOW" family) speeds the inflammation resolution that otherwise gates repair.

Notes

• KPV is also available in oral forms (stable-ish, community use) — but the injectable is the standard for research protocols.
• KPV does NOT cause skin tanning (unlike Melanotan family) — a common confusion; worth an FAQ entry.
• Pairs with curcumin/omega-3s (supplement layer) without interaction concerns.

Sources

[57] [58] [59] [85]

CARD 09 — SERMORELIN + IPAMORELIN (Beginner GH / Anti-Aging)

Tags: 🟢 CLINICAL (sermorelin has FDA history for GHD diagnosis/treatment; ipamorelin selectivity clinical) | RUO ONLY

Goal

Gentle GH-axis support for anti-aging, sleep, recovery, and body composition — the beginner GH stack and the standard "first secretagogue protocol" in clinics.

Rationale

• Sermorelin (GRF 1-29) — the original GHRH analog, with the longest human use history in the GHRH family (FDA-approved for pediatric GHD diagnosis and treatment in its time). Gentle, short pulses, aligned to nocturnal rhythm.
• Ipamorelin — the selective GHRP partner (same synergy logic as Card 03).
• Vs. CJC-1295 no DAC + ipamorelin: sermorelin is gentler and shorter-acting; CJC no DAC produces a stronger/longer pulse. For users >50, sensitized to sides, or new to the GH axis, sermorelin + ipamorelin is the standard entry point; CJC/Ipa is the upgrade path.

Peptides & doses

| Component | Dose | Frequency | |---|---|---| | Sermorelin | 250–500 mcg | Nightly (or 5 on/2 off) | | Ipamorelin | 150–300 mcg | Same schedule |

Timing

• Pre-bed, fasted ≥2 h. Same syringe is standard. Some protocols dose sermorelin 1–2×/day (AM + pre-bed) in later phases.

Cycle

• 6–12 months for anti-aging indications (clinics run long cycles with 1–3 months off periodically). Body-composition users run 12-week blocks with 4 weeks off.

What to expect

• Sleep quality within 2–4 weeks; skin/tissue quality and body composition over 3–6 months.
• Results are subtle and slow — set expectations accordingly (this is the gentle tier).

Notes

• Monitor IGF-1 every 8–12 weeks; keep in upper-normal range.
• Best first GH-axis experience: lowest side-effect burden of the GHRH options, near-zero cortisol effect when paired with ipamorelin.

Sources

[8] [11] [68] [69-ish list]

CARD 10 — CJC-1295 no DAC + IPAMORELIN + MK-677 (Advanced GH, High-Monitoring)

Tags: 🔴 COMMUNITY (combination) / 🟡 MIXED (MK-677 has 12-month human trial data) | WADA ⛔ | RUO ONLY | FDA-FLAGGED (CJC-1295) | HIGH-RISK LABEL

Goal

Maximum endogenous GH/IGF-1 elevation: aggressive recomp, muscle recovery, deep sleep. The "everything GH" protocol — for experienced users who understand the metabolic cost.

Rationale

• CJC-1295 no DAC + ipamorelin = the pulsatile GHRH+GHRP layer (Card 03).
• MK-677 (oral ghrelin mimetic) adds a tonic GH elevation on top of the pulses — community rationale: "pulses + baseline." The problem is the tonic layer is precisely what drives the metabolic side effects.
• Clinical anchor for the warning: in a 12-month randomized trial in older adults (Nass et al., Ann Intern Med 2008), MK-677 increased lean mass modestly but reduced insulin sensitivity, raised fasting glucose, raised HbA1c (+0.2%), caused edema, and increased appetite — these are not hypotheticals.

Peptides & doses

| Component | Dose | Frequency | Route | |---|---|---|---| | CJC-1295 no DAC | 100–200 mcg | 1–2×/day fasted | SubQ | | Ipamorelin | 200–300 mcg | 1–2×/day fasted | SubQ | | MK-677 | 10–25 mg | Nightly | Oral |

Timing

• CJC/Ipa fasted AM + pre-bed; MK-677 at bedtime (leverages nocturnal surge). Community "alternating" variant: run MK-677 only on non-CJC/Ipa days or weekends to reduce insulin-resistance pressure.

Cycle

• 8–12 weeks on, 4–8 weeks off (MK-677 longer off-periods). Community warns: never run this continuously.

What to expect

• Strong sleep/vivid dreams, appetite increase (MK-677), water retention in weeks 1–3, measurable IGF-1 rise by weeks 3–4, body-composition effects 9–16 weeks. Expect transient numbness/tingling (fluid retention compressing nerves — carpal-tunnel-like).

Notes

• Contraindicated: diabetes, pre-diabetes, active cancer. Mandatory monitoring: fasting glucose, HbA1c, HOMA-IR, IGF-1, blood pressure — every 4 weeks.
• This is the exact stack shape that produced the "5-peptide casualty" cautionary stories in the community (bloating, insulin resistance, moon face) when more GH agents were piled on. Treat the +MK-677 layer as the ceiling, never the floor.
• If fasting glucose creeps >100 mg/dL (5.6 mmol/L) or HOMA-IR rises, stop the MK-677 layer first.

Sources

[43] [44] [70] [71] [72] + Nass 2008 in Bibliography.

CARD 11 — AOD-9604 + HGH FRAG 176-191 (+ TESAMORELIN) — Targeted Lipolysis

Tags: 🟡 MIXED (AOD-9604 has clinical-trial history ~900 subjects; HGH Frag mostly animal data; stack = community) | WADA ⛔ | RUO ONLY

Goal

Lipolysis-focused fat loss without appetite suppression or systemic GH elevation — for users who want fat-burning support without the hunger/insulin effects of MK-677 or the appetite loss of GLP-1s.

Rationale

• AOD-9604 — stabilized fragment of hGH (aa 176–191, +N-term Tyr): designed by Monash University / Metabolic Pharmaceuticals to isolate GH's fat-mobilization effect (lipolysis via β3-adrenergic signalling) without GH receptor/IGF-1 effects. Clinical trials (~900 participants) showed modest fat loss — order of 1–2 kg additional fat loss over 12 weeks at 1 mg/day vs placebo. Community dose is 300–500 mcg/day, which is below trial doses — set expectations accordingly.
• HGH Frag 176-191 — the unmodified fragment; similar mechanism, weaker stability, mostly animal-data support; used interchangeably in the community at 250–500 mcg 1–2×/day.
• Tesamorelin (optional add) — adds the endogenous GH layer that AOD lacks, targeting visceral fat (Card 04 logic). Community stack: GLP-1 (appetite) + AOD-9604 (lipolysis) + tesamorelin (visceral + muscle) is a "full metabolic" protocol.

Peptides & doses

| Component | Dose | Frequency | Timing | |---|---|---|---| | AOD-9604 | 300–500 mcg | Daily (or 5 on/2 off) | Fasted AM, 30–60 min before food/exercise | | HGH Frag 176-191 (alternative/adjunct) | 250–500 mcg | 1–2×/day | Fasted | | Tesamorelin (optional) | 1 mg | Daily | Pre-bed fasted |

Timing

• Fasted windows maximize lipolysis signalling (low insulin). AOD pre-cardio is the community favorite.

Cycle

• 4–12 weeks on, 2–4 weeks off.

What to expect

• Slow, modest fat loss; works best in a caloric deficit with cardio; does NOT suppress appetite (that's the GLP-1 layer's job) and does NOT raise IGF-1.
• Realistic framing: an adjunct, not a dramatic fat-loss drug — the trials show single-digit kg effects over months at 1 mg/day.

Notes

• AOD-9604 does not meaningfully affect blood sugar/insulin — safe in insulin-resistant users (unlike MK-677).
• HGH Frag 176-191 vs AOD-9604: community consensus favors AOD for stability/reconstitution reliability; the fragment is the "raw" version.
• WADA: both are prohibited for athletes (GH fragments).

Sources

[47] [48] [49] [50] [51] [74]

CARD 12 — THYMOSIN ALPHA-1 + EPITALON + GHK-Cu (Immune / Longevity)

Tags: 🟢 CLINICAL (thymosin alpha-1 has real clinical history; GHK-Cu topical clinical) / 🟡 MIXED (Epitalon: animal/telomerase data, Russian clinical tradition, thin Western human data) | RUO ONLY

Goal

Immune resilience (immunosenescence support), cellular longevity signalling, and structural repair — the "seasonal longevity reset."

Rationale

• Thymosin Alpha-1 (Tα1) — 28-aa thymic peptide; enhances T-cell function, modulates inflammation via TLR signalling; has a genuine clinical evidence base (adjuvant in infections, immune deficiency, some oncology settings — see the comprehensive review, PMC7747025). Community immune-support dose: 1.6 mg 2×/week.
• Epitalon (Epithalon) — synthetic tetrapeptide (Ala-Glu-Asp-Gly) associated with telomerase activation and pineal/rhythm effects in the Khavinson school of Russian peptide research; animal lifespan data; human use is tradition + small studies, not modern RCTs. Community protocol: 10 mg nightly for 10–20 day courses, 2–3×/year.
• GHK-Cu — the structural/anti-aging layer (Card 01 logic).
• The trio = immune (Tα1) + longevity signal (Epitalon) + structural repair (GHK-Cu) — three different mechanisms, three axes-adjacent layers.

Peptides & doses

| Component | Dose | Frequency | Route | |---|---|---|---| | Thymosin Alpha-1 | 1.6 mg (or 1–2 mg) | 2×/week, 12-week cycles | SubQ | | Epitalon | 10 mg | Nightly × 10–20 days, 2–3×/year | SubQ | | GHK-Cu | 1–2 mg/day (injectable) OR topical 1–2% serum | Daily, 8–12 week cycles | SubQ / topical |

Timing

• Tα1: morning (some report immune stimulation); Epitalon: pre-bed; GHK-Cu: evening or per skin routine. Separate syringes.

Cycle

• Tα1: 12 weeks on, repeat 2–3×/year; Epitalon: short pulse cycles (10–20 days) 2–3×/year; GHK-Cu: 8–12 weeks on, 4–6 weeks off.

What to expect

• Tα1: fewer/shortened infections, better energy during illness season (community + clinical signal); Epitalon: improved sleep rhythm, subjective vitality (largely anecdotal in the West); GHK-Cu: skin quality (clinical for topical).

Notes

• Epitalon + cancer history = contraindicated (telomerase activation theoretical tumor risk).
• Tα1 is the most clinically legitimate immune peptide in the catalogue — lead with it on the immune card.
• Tα1 is also used as the "immune layer" in advanced recovery stacks (BPC-157 + Tα1 during illness or surgery recovery) — compatible, separate syringes.

Sources

[63] [64] [65] [35] [38]

7. AVOID-LIST — BAD COMBINATIONS AND WHY

Publish this as a dedicated page. Each entry: the combo, the reason, the safer alternative.

❌ 1. Multiple GHRPs at once (GHRP-2 + GHRP-6 + hexarelin + ipamorelin...)

• Why: All GHRPs act through the same receptor (GHSR-1a). Stacking them is receptor redundancy, not synergy — the extra compounds add cortisol/prolactin (GHRP-2, GHRP-6, hexarelin all raise ACTH/cortisol per Raun 1998 and FDA 2023 flags) and side effects without adding GH release.
• Safer: One selective GHRP (ipamorelin) + one GHRH (CJC no DAC / sermorelin / tesamorelin).

❌ 2. CJC-1295 WITH DAC + daily GHRP

• Why: The DAC version creates a 6–8-day tonic GH signal. Adding a daily GHRP piles pulsatile release on top of a constant signal → somatotroph desensitization, IGF-1 overshoot, water retention, "moon face," and insulin resistance. Weekly-DAC protocols are a different protocol style (dose GHRP only around the weekly window, or don't combine at all).
• Safer: CJC-1295 no DAC (Mod GRF 1-29) + ipamorelin, daily, cycled.

❌ 3. MK-677 + CJC-1295 DAC + GHRP-6 (the "5-peptide GH pile-on")

• Why: This is the community's cautionary tale — three tonic/pulsatile GH stimuli at once. Documented MK-677 effects (Nass 2008: reduced insulin sensitivity, +HbA1c, edema, appetite) get compounded. Expect bloating, insulin resistance, carpal-tunnel numbness, and rapid fat regain.
• Safer: Card 10 at most (no-DAC + ipamorelin + MK-677, monitored) — and that is already the aggressive ceiling.

❌ 4. GHRP-6 / GHRP-2 in any stack for non-bulking goals

• Why: Cortisol + prolactin elevation (Raun 1998; FDA 2023 safety list), extreme appetite spikes, and immunogenicity concerns flagged by FDA. The appetite spike is sometimes wanted for bulking — but the cortisol cost makes it a poor trade in almost every stack.
• Safer: ipamorelin (selective) for GH; MK-677 for appetite (still monitor glucose).

❌ 5. BPC-157 (or TB-500) with active cancer / cancer history

• Why: BPC-157 upregulates VEGFR2 and drives angiogenesis; TB-500 promotes cell migration. In cancer, new blood vessels feed tumors and migration aids spread. The 2023 pharmaceutical review flagged this as a theoretical but serious concern; there is no human safety data. Not a risk worth taking.
• Safer: Non-angiogenic support only (KPV for inflammation, GHK-Cu topical, NAD+).

❌ 6. GHK-Cu co-formulated or co-stored with other peptides in the same vial

• Why: The copper chelate is chemically fragile; it degrades faster than other peptides (color shift azure → green-brown = degradation), and metal-ion + peptide co-solution is the #1 documented blend-stability risk. Long-term co-storage destroys the whole vial's expiry clock.
• Safer: Reconstitute GHK-Cu separately; draw into the same syringe only immediately before injection (community-accepted for GLOW-type stacks), or inject separately.

❌ 7. GLP-1s (semaglutide/tirzepatide/retatrutide) mixed with anything in one syringe

• Why: Formulation incompatibility — GLP-1 drug products have specific pH/buffer/excipient requirements; mixing risks precipitation and potency loss. Also, commercial "tirzepatide + BPC-157 blend" products are marketing, not validated formulations.
• Safer: Separate injections, separate sites, separate days if desired.

❌ 8. IGF-1 LR3 + GH secretagogues

• Why: Exogenous IGF-1 on top of secretagogue-driven IGF-1 = uncontrolled IGF-1 elevation → organ stress, hypoglycemia (IGF-1 is a potent glucose-lowering agent), edema, jaw growth risk in high doses. This is the "double-dip" of the GH axis.
• Safer: Choose the endogenous route (secretagogues) OR the exogenous route (IGF-1), never both.

❌ 9. Epitalon / telomerase-activators with cancer history

• Why: Telomerase activation is the theoretical mechanism of benefit and equally the theoretical mechanism of risk in neoplastic cells.
• Safer: Skip the telomerase layer; use Tα1 + NAD+ instead.

❌ 10. GH-axis stacks with high-carb meal timing (i.e., breaking the 2-hour fast rule)

• Why: Insulin blunts the GH response via somatostatin. Injecting after a meal is injecting into a brake. Not "dangerous" but 100% wasted product — the most common silent protocol failure.
• Safer: 2 h fast before, 30–60 min after, for every Axis A injection.

❌ 11. Semaglutide + Tirzepatide together

• Why: Receptor overlap (both GLP-1; tirzepatide also GIP). Community "low-dose combo" claims exist but are controversial; side-effect burden compounds (GI, gallbladder, retinopathy flags on labels). No trial data supports benefit.
• Safer: Pick one; add retatrutide only in trials/research contexts (Card 07), never both GLP-1s.

❌ 12. Aggressive GHRP + GLP-1 appetite wars (GHRP-6 + semaglutide)

• Why: GHRP-6's extreme appetite spike directly fights the GLP-1's appetite suppression. You get nausea + hunger simultaneously, insulin/cortisol chaos, and no clear win.
• Safer: GLP-1 + BPC-157 (tolerance), or GLP-1 + tesamorelin (visceral + muscle).

❌ 13. Long-duration continuous GH-axis use (no cycling)

• Why: Somatotroph downregulation, persistent insulin resistance, water retention, and IGF-1-driven tissue growth risks. Cycling is not optional for Axis A.
• Safer: 8–12 weeks on / 4 weeks off, labs at cycle start and end.

❌ 14. Mixing peptides with incompatible solvents

• Why: Some peptides (e.g., melanotan/PT-141 families) are formulated in acetic-acid water; others (most of our catalogue) in bacteriostatic water. Mixing solvent systems precipitates product. Also: never add solvents not specified by the vendor COA.
• Safer: Follow per-product reconstitution sheets; keep acetic-acid and BAC-water peptides in separate syringes.

❌ 15. Untested product in any stack

• Why: With 3+ compounds, a single bad vial poisons the whole protocol and you can't attribute sides. The community standard is third-party HPLC/MS verification (Janoshik-style COAs with verifiable unique keys).
• Safer: Batch-verified product only; log batch numbers per vial per cycle.

8. BEGINNER VS ADVANCED STACK TIERS

Publish as a decision-tree page. The tiers are about protocol complexity and monitoring burden, not about "stronger = better."

TIER 0 — Foundations (everyone, always)

• Sleep 7–8 h, protein 1.6–2.2 g/kg, resistance training, caloric control, micronutrient baseline (zinc, magnesium, vitamin D, omega-3), labs drawn.
• Allowed: GHK-Cu topical (clinical skin evidence is the strongest in the catalogue), oral NAD+ precursors (NR/NMN 250–500 mg/day), collagen + copper nutrition (GHK-Cu works on copper-dependent enzymes — 2–3 mg/day copper via diet is the context that makes GHK-Cu signalling possible).
• No injections, no stacks. This tier alone delivers most of the "anti-aging" benefit people attribute to peptides.

TIER 1 — Beginner (one compound, one axis)

| Stack | Axis | Notes | |---|---|---| | BPC-157 solo (250–500 mcg/day, 4–8 wk) | B | Injury/gut single-compound entry; learn reconstitution, injection, cycle discipline | | Sermorelin + Ipamorelin (Card 09) | A | The gentle GH entry; longest clinical history per component | | AOD-9604 solo (300–500 mcg/day) | C | Fat-loss adjunct, no GH sides | | GHK-Cu topical + oral collagen/copper | B | Skin first; zero injection risk |

Beginner rules: one compound at a time; 2-week observation before adding anything; no GH-axis compound without baseline fasting glucose + IGF-1.

TIER 2 — Intermediate (two axes, or the classic two-compound pairs)

| Stack | Axes | Why here | |---|---|---| | Wolverine (BPC-157 + TB-500) — Card 02 | B | Two-axis-B layers, different mechanisms; the standard injury protocol | | CJC-1295 no DAC + Ipamorelin — Card 03 | A | The GH recomp standard; requires fasting discipline + labs | | Tesamorelin + Ipamorelin — Card 04 | A | Visceral fat + muscle; blood-sugar monitoring required | | NAD+ + MOTS-c — Card 05 | C | Mitochondrial energy; learn injection tolerance of NAD+ | | KPV + BPC-157 — Card 08 | B | Gut/inflammation | | GLOW — Card 01 | B | Three-layer repair; reconstitution complexity (copper) |

Intermediate rules: one new compound per week max; know the half-life of everything you inject; labs at start/mid/end of GH-axis cycles.

TIER 3 — Advanced (cross-axis, high monitoring)

| Stack | Axes | Why it's advanced | |---|---|---| | GLP-1 + BPC-157 (Card 06) | C + B | Two drug classes; sequencing + GI management skill | | Retatrutide + Tesamorelin + MOTS-c (Card 07) | C + A | Three compounds, cardiac/glucose monitoring, deep-deficit nutrition | | CJC no DAC + Ipa + MK-677 (Card 10) | A (x2 mechanisms + tonic) | Insulin-resistance risk; monthly glucose/HbA1c mandatory | | GLP-1 + Wolverine/GLOW (full recomp) | C + B | The "everything" protocol; cost, injection load, side-effect stacking all real | | Tα1 + Epitalon + GHK-Cu (Card 12) | Immune + B | Seasonal longevity; contraindication screening (cancer) |

Advanced rules: all Tier-2 rules plus: quarterly labs, blood-pressure log (GH + glucagon agents), body-weight/waist log, and a written stop-criteria list (glucose >100 mg/dL fasting, HbA1c +0.5, resting HR +10 bpm sustained, uncontrolled edema, new numbness, chest symptoms).

Tier progression philosophy (publish this line)

"Tiers are not a race. The difference between Tier 1 and Tier 3 outcomes is mostly nutrition, training, sleep, and compliance — the peptides contribute the same 10–20% at every tier."

9. RECONSTITUTION, STORAGE, AND SYRINGE-MIXING RULES

9.1 Reconstitution

• Solvent: bacteriostatic water (0.9% benzyl alcohol) for the standard catalogue; follow the per-product COA/vendor sheet for anything else (acetic-acid families exist — never swap solvents).
• Technique: inject solvent slowly down the vial wall; do not jet directly onto the lyophilized cake; swirl (never shake) to dissolve; wait for full clarity.
• Concentration math: dose (mcg) ÷ vial mg × reconstitution mL = mL to draw. Always publish a calculator link on the site (e.g., 5 mg vial + 2 mL BAC → 2.5 mg/mL → 500 mcg = 0.2 mL = 20 units U-100).

9.2 Storage

| State | Temperature | Shelf life | |---|---|---| | Lyophilized (powder) | −20 °C (fridge acceptable short-term; −80 °C ideal long-term) | Per COA (12–24 mo typical) | | Reconstituted (standard peptides) | 2–8 °C, upright, light-protected | 4–6 weeks | | Reconstituted GLOW/blends with GHK-Cu | 2–8 °C, upright, light-protected | ~4 weeks MAX — color is the clock (azure → green-brown = discard) |

• Never freeze reconstituted peptide. Freeze-thaw cycles shear bonds and break the copper chelate. Aliquot powder before reconstitution if long storage is needed.
• GHK-Cu: more stable than reputation when handled right, but sensitive to pH extremes, ROS, and chelators — keep away from EDTA-containing anything.

9.3 Syringe mixing — what the evidence/community says

| Pair | Mix in syringe? | Notes | |---|---|---| | BPC-157 + TB-500 | ✅ Yes | Most common mix; draw BPC first, inject immediately | | CJC-1295 no DAC + Ipamorelin | ✅ Yes | Standard practice | | Tesamorelin + Ipamorelin | ✅ Yes | Same session OK | | Sermorelin + Ipamorelin | ✅ Yes | Same session OK | | + GHK-Cu into BPC/TB-500 | ⚠️ Yes, immediately before injection | Fine short-coexistence; never store mixed | | MOTS-c / NAD+ / GLP-1 / PT-141 / GHK-Cu with unrelated peptides | ❌ No | Separate syringes, separate sites | | Any two peptides with different solvent systems | ❌ No | Precipitation risk |

• Rules: total volume ≤2 mL per site; subQ with subQ only (don't mix routes); inject within minutes of drawing; never pre-fill syringes for later use; if in doubt, two injections beat one risky one.

10. LAB MONITORING PANEL

Publish as a "Labs for every stack" table.

| Marker | When | Why | |---|---|---| | IGF-1 | Baseline, wk 4, wk 8–12 of every Axis A cycle | Catch GH overdrive; keep upper-normal | | Fasting glucose + HbA1c + HOMA-IR | Baseline, monthly on MK-677/tesamorelin/high-GH stacks | GH is counter-regulatory; MK-677 proven to impair insulin sensitivity | | Lipid panel (LDL/HDL/TG) | Baseline + end of metabolic cycles | Tesamorelin improves TG; GH can worsen lipids | | Liver (ALT/AST) + kidney (BUN/Cr) | Baseline + end of any injectable cycle | Peptide/impurity load; injection hygiene | | CRP / hs-CRP | Baseline + end | Track the inflammation axis (BPC-157/KPV protocols) | | CBC + differential | Baseline + during Tα1 protocols | Immune modulation tracking | | TSH / fT4 | Baseline + during GH stacks | GH alters T4→T3 conversion | | Free T / estradiol | Baseline + end of long stacks | Context for recomp claims; not a peptide effect per se | | BP + resting HR | Weekly during retatrutide/high-GH stacks | Glucagon/GH cardiovascular load | | Copper/zinc status | Before + during long GHK-Cu injectable protocols | Long-term high-dose copper; avoid deficiency swings | | Albumin | If dosing CJC-DAC | DAC binds albumin |

Stop-and-consult triggers: fasting glucose >100 mg/dL (5.6 mmol/L) sustained; HbA1c +0.5 or crossing 5.7%; IGF-1 above age-adjusted upper limit; uncontrolled edema; resting HR +10 bpm sustained; new numbness/tingling; chest symptoms; any allergic/injection-site reaction beyond mild erythema.

11. FULL BIBLIOGRAPHY WITH URLs

Peer-reviewed / clinical (primary)

1. Falutz J, et al. Effect of tesamorelin vs placebo on visceral fat in HIV-infected patients with abdominal fat accumulation. N Engl J Med 2007;357:2359–2367. https://pubmed.ncbi.nlm.nih.gov/17957317/
2. Falutz J, et al. 12-month tesamorelin: continued VAT reduction and safety. AIDS 2010 (and NEJM 2010 follow-up reports). https://www.innerbody.com/tesamorelin (summary)
3. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139(5):552–561. https://pubmed.ncbi.nlm.nih.gov/9849822/ | https://academic.oup.com/ejendo/article-abstract/139/5/552/6748390
4. Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med 2008. https://pmc.ncbi.nlm.nih.gov/articles/PMC2757071/
5. Pickart L, et al. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
6. Jastreboff AM, et al. Retatrutide phase 2 trial. N Engl J Med 2023;389:514–526. https://pubmed.ncbi.nlm.nih.gov/37272522/
7. Jastreboff AM, et al. SURMOUNT-1: Tirzepatide once weekly. N Engl J Med 2022. https://pubmed.ncbi.nlm.nih.gov/35658024/
8. Wilding JPH, et al. STEP 1: Semaglutide 2.4 mg. N Engl J Med 2021. https://pubmed.ncbi.nlm.nih.gov/33567185/
9. Lee C, et al. MOTS-c: A mitochondrial-encoded regulator of metabolism. Nat Commun 2015. https://pubmed.ncbi.nlm.nih.gov/25686641/
10. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol / Curr Pharm Des (review). https://pmc.ncbi.nlm.nih.gov/articles/PMC8275860/
11. BPC-157 organoprotection review. Gut Liver 2019. https://www.gutnliver.org/journal/view.html?doi=10.5009/gnl18490
12. BPC-157 regeneration & analgesia review. Int J Mol Sci 2026;27(6):2876. https://www.mdpi.com/1422-0067/27/6/2876
13. McGuire FP, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
14. Lee E, Burgess K. Safety of intravenous infusion of BPC-157 in humans: a pilot study. Altern Ther Health Med 2025 (via WellFounded audit). https://wellfounded.health/insights/bpc-157-and-the-difference-between-an-evidence-gap-and-a-cover-up
15. Thymosin alpha-1: a comprehensive review. World J Clin Oncol (PMC). https://pmc.ncbi.nlm.nih.gov/articles/PMC7747025/
16. Saving muscle while losing weight on GLP-1 drugs. World J Gastroenterol / review (PMC). https://pmc.ncbi.nlm.nih.gov/articles/PMC12444289/
17. Clinical recommendations to manage GI adverse events of GLP-1 RAs. https://pmc.ncbi.nlm.nih.gov/articles/PMC9821052/
18. Veldhuis JD, Bowers CY. GHRH + ghrelin-receptor co-activation synergy (framework cited via Superpower Labs review). https://superpower.com/guides/cjc-1295-ipamorelin-stack

Regulatory

19. FDA — Certain bulk drug substances that may present significant safety risks (503A list incl. CJC-1295, GHRP-2, GHRP-6; BPC-157/TB-500 flagged 2023). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
20. Missouri Poison Center — Is peptide stacking dangerous? https://missouripoisoncenter.org/peptide-stacking

Vendor / protocol guides (community-standard protocols)

21. GLOW: https://peptidesexplorer.com/blog/ghk-cu-bpc-157-tb-500-blend-dosage | https://peptidemind.com/peptides/glow-protocol | https://peptidedosages.com/peptide-blend-dosages/glow-peptide-blend-70-mg-vial-dosage-protocol | https://calorize.com.ua/en/peptides/glow | https://www.redfoxpeptides.is/ghk-cu-copper-peptide-complete-guide
22. GLOW storage/stability: https://palmettopeptides.com/blogs/news/glow-stack-storage-reconstitution | https://palmettopeptides.com/blogs/news/05-ghk-cu-storage-handling-stability | https://parahealth.de/en/blogs/blog/glow-stack-blend-ghk-cu-tb500-bpc157
23. Wolverine: https://peptiq.io/blog/bpc-157-tb-500-stacking-injury-recovery-guide | https://www.perfectb.com/wolverine-peptide-bpc-157-tb-500 | https://coremedicalwellness.com/wolverine-stack-for-pain-bpc-157-tb-500-recovery-chronic-pain-guide-2026 | https://moonshotmp.com/learn/wolverine-blend | https://denverregenerativemedicine.com/wolverine-peptide-stack-injury-recovery-gh-restoration-glp1 | https://driphydration.com/blog/wolverine-stack-injury-recovery
24. CJC-1295 + Ipamorelin: https://peptidesexplorer.com/blog/cjc-1295-dosage-guide | https://peptidemind.com/peptides/cjc-ipa-protocol | https://peptiq.io/blog/cjc-1295-ipamorelin-stack-guide | https://www.perfectb.com/cjc-1295-ipamorelin-dosage-protocol | https://riteaid.com/peptides/cjc-1295 | https://swolverine.com/blogs/blog/ipamorelin-cycle-guide-optimal-dosage-timing-and-best-peptide-stacks
25. Tesamorelin stacks: https://www.perfectb.com/tesamorelin-dosage-protocol | https://pantheonpeptides.tawk.help/article/ipamorelin-tesamorelin-stack-5mg-2mg | https://jaycampbell.com/blog/tesamorelin-and-ipamorelin-blend-benefits | https://riteaid.com/peptides/stacks/tesamorelin-and-ipamorelin | https://www.creeksidefamilypractice.com/post/tesamorelinipamorelin | https://www.redfoxpeptides.is/retatrutide-tesamorelin-stack-protocol
26. GLP-1 + peptides: https://www.redfoxpeptides.is/best-peptides-to-stack-with-tirzepatide | https://www.impacthealthclinics.com/blog/glp1-stacking-tirzepatide-semaglutide-complete-guide | https://formblends.com/articles/peptide-hub/bpc-157-with-glp-1-stacking-guide | https://prestigemedigroup.com/the-benefits-of-semaglutide-with-bpc-157-while-monitoring-your-progress-with-inbody
27. Retatrutide stacks: https://peptidefox.com/content/retatrutide-dual-axis | https://www.redfoxpeptides.is/peptides-to-stack-with-retatrutide | https://www.californiatrimclinic.com/retatrutide-mots-c-the-elite-metabolic-stack-redefining-fat-loss | https://lamkinclinic.com/3-tier-peptide-stacking
28. NAD+ / MOTS-c: https://peptiq.io/blog/aod-9604-fat-loss-guide (incl. NAD+/MOTS-c framing) | MOTS-c dosing guides: PeptIQ "MOTS-C and NAD+: Do They Work Together?" | Healthspan "MOTS-C Dosage Chart" | Perfect B MOTS-c protocol (5 mg/5 days)
29. MK-677 stacks: https://www.pathtopeptides.com/cjc-1295-ipamorelin-mk677-stack-protocol.html | https://swolverine.com/blogs/blog/mk-677-for-beginners-what-you-need-to-know-about-growth-recovery-and-sleep | https://healingmaps.com/mk-677-ibutamoren-guide | https://peptidesexplorer.com/peptides/mk-677 | https://nurevpeptides.com/the-best-peptides-for-recovery-bpc-157-tb500-mk-677-ipamorelin-cjc-1295-and-more-a-complete-guide-to-enhanced-healing
30. AOD-9604 / HGH Frag: https://www.bhrcenter.com/aod-9604-dosage-guide-complete-protocol-for-safe-administration | https://www.perfectb.com/aod-9604-peptide-hgh-fragment-fat-loss | https://edgeweightlossfatigue.com/aod-9604-dosage-guide | https://www.reddit.com/r/PeptideForum/comments/1crvtef/aod_9604_questions | https://www.reddit.com/r/healthybiohacking/comments/1q6ku97/weight_loss_peptides_cycle_schedule
31. KPV: https://peptidesexplorer.com/blog/kpv-peptide-dosage | https://aminoinnovations.com/kpv-peptide-dosage-guide | https://www.realpeptides.co/can-you-stack-bpc-157-kpv | https://preferredregen.com/blog/the-bpc-157-tb-500-kpv-ghk-cu-peptide-stack-guide
32. GHK-Cu clinical context: https://www.empiremedicaltraining.com/antiaging-regenerative-workshops/resources/peptide-therapy/ghk-cu | https://nubeeannoosa.com.au/blogs/news/copper-peptides-injection-vs-topical | https://plasticsurgerykey.com/ghk-cu-peptides-before-and-after-dosage-benefits-how-it-works-for-skin-and-hair | https://www.westlakedermatology.com/trends/ghk-cu-copper-peptides-for-skin-care
33. Longevity/immune stacks: https://formblends.com/articles/longevity-hub/longevity-peptide-stacks | https://www.peakhealthinstitute.com/best-peptide-stacks-for-health-and-longevity-2025-guide | https://www.longevitycville.com/blog/the-power-of-peptides-unlocking-healing-regeneration-and-longevity
34. Mixing peptides: https://peptidejournal.org/faq/can-you-mix-different-peptides-together | https://peptiq.io/blog/can-you-mix-peptides-in-same-syringe | https://www.seekpeptides.com/blog/articles/peptide-stacks-guide | https://www.linkedin.com/posts/jonathannkuo_peptidetherapy-longevitymedicine-regenerativehealth-activity-7311431335259107329-VnEs
35. Safety / stacking risk: https://stridekick.com/blog/peptide-stacking-for-fat-loss-and-longevity-is-it-legit | https://driphydration.com/blog/peptide-stacking | https://kingkillers.co/blogs/news/the-kingkillers-peptide-stacking-guide-how-to-combine-bpc-157-tb-500-ipamorelin-cjc-1295-and-retatrutide | https://www.orthoandwellness.com/blog/bpc-157-update-and-deep-dive-miracle-healing-peptide-or-hidden-danger
36. Community/netnography: https://www.sciencedirect.com/science/article/pii/S2211266924000306 | https://www.reddit.com/r/ACL/comments/1jwe0oe/documenting_my_aclr_meniscus_repair_journey | https://www.reddit.com/r/Peptides/comments/1qr4qky/bpc157tb500_kvp | https://www.reddit.com/r/PeptideForum/
37. Vendor product/protocol pages: https://swisschems.is/product/bpc-157-tb-500-blend | https://swisschems.is/product/healing-research | https://www.durhampeptides.ca/post/bpc-157-vs-ghk-cu-comparison (Janoshik COA verification practice)

APPENDIX A — Quick-reference cheat sheet (for internal use; optional site infographic)

| Stack | Compounds | Daily total | Cycle | Tier | |---|---|---|---|---| | GLOW | GHK-Cu 1.4–1.7 mg + BPC 0.3 mg + TB-500 0.3 mg | ~2–2.5 mg | 4 wk on / 2–4 off | 2 | | Wolverine | BPC 250–500 mcg + TB-500 2.5 mg 2×/wk | — | 4–12 wk | 2 | | CJC/Ipa | CJC 100–200 mcg + Ipa 200–300 mcg | 2–3×/day | 8–12 wk on / 4 off | 2 | | Tesa/Ipa | Tesa 1–2 mg + Ipa 100–300 mcg | daily | 12–24 wk | 2 | | NAD+/MOTS-c | NAD+ 50–200 mg IM 2–3×/wk + MOTS-c 5–10 mg 2–3×/wk | — | 4–6 wk blocks | 2 | | GLP-1+BPC | GLP-1 per label + BPC 250–500 mcg | — | titration phase | 3 | | Reta+Tesa+MOTS-c | Reta 2–8 mg/wk + Tesa 1 mg + MOTS-c 5 mg 2×/wk | — | 12+ wk | 3 | | KPV+BPC | KPV 200–500 mcg + BPC 250–500 mcg | — | 4–8 wk | 2 | | Sermorelin/Ipa | Serm 250–500 mcg + Ipa 150–300 mcg | nightly | 6–12 mo | 1 | | CJC/Ipa+MK-677 | Card 10 + MK-677 10–25 mg oral | — | 8–12 wk on / 4–8 off | 3 | | AOD/Frag | AOD 300–500 mcg (or Frag 250–500 mcg ×2) | daily | 4–12 wk | 1–2 | | Tα1+Epitalon+GHK-Cu | Tα1 1.6 mg 2×/wk + Epitalon 10 mg ×10–20 d + GHK-Cu 1–2 mg | — | seasonal | 3 |

APPENDIX B — Editorial rules for the website team (VALEN LABS voice)

1. Every card keeps the RUO banner and the evidence tag. No exceptions.
2. "Clinical" claims only where the bibliography has a human trial; otherwise use "preclinical data suggest" or "community protocols use."
3. Never publish a dose as "the dose" — always "community-standard research dose" / "typical protocol," and always "under qualified supervision."
4. Every card ends with the amplifier line: "Peptides are amplifiers of a healthy protocol, not replacements for one."
5. Serbia/EU framing: these are research substances; local purchase/sale must comply with the Serbian Law on Medicines and Medical Devices and EU regulatory frameworks; no medical claims.
6. Keep the avoid-list live — it is the page that builds trust and differentiates VALEN LABS from vendors who will sell anyone anything.

End of knowledge base v1.0. Next review: after any new phase-3 data (retatrutide approval status), new BPC-157 human trials, or regulatory changes in EU/Serbia.